The complexity of signaling networks driving advanced cancers has given rise to several multi-targeted strategies, including the use of complex drug cocktails, hybrid or chimeric molecules (e.g., HDAC-tyrosine kinase inhibitors such as HDAC-EGFR/Her2, HDAC-PDGFR inhibitors, and microtubule disruptors) which are in preclinical/clinical stages of evaluation or currently being used in the clinic [37,38,39,40,41,42]. This evidence concerns the gene EGFR and cancer.